MRI-guided laser ablation of neuroendocrine tumor hepatic metastases.
BACKGROUND
Neuroendocrine tumors (NET) represent a therapeutically challenging and heterogeneous group of malignancies occurring throughout the body, but mainly in the gastrointestinal system.


OBJECTIVE
To describe magnetic resonance imaging (MRI)-guided laser ablation of NET liver metastases and assess its role within the current treatment options and methods.


METHODS
Two patients with NET tumor hepatic metastases were treated with MRI-guided interstitial laser ablation (LITT). Three tumors were treated. Clinical follow-up time was 10 years.


RESULTS
Both patients were successfully treated. There were no local recurrences at the ablation site during the follow-up. Both patients had survived at 10-year follow-up. One patient is disease-free.


CONCLUSIONS
MRI-guided laser ablation can be used to treat NET tumor liver metastases but combination therapy and a rigorous follow-up schedule are recommended.
Department of Radiology, Oulu University Hospital, Oulu, Finland.
Jukka
J
Perälä
Department of Radiology, Southern Ostrobothnia Hospital, Seinäjoki, Finland.
Rauli
R
Klemola
Department of Oncology, Oulu University Hospital, Finland.
Raija
R
Kallio
Shandong Provincial Medical Imaging Research Institute, Shandong University, Jinan, Shandong, PR China.
Chengli
C
Li
Department of Medicine, Central Ostrobothnia Hospital, Kokkola, Finland.
Ilkka
I
Vihriälä
Department of Medicine, Division of Endocrinology, Oulu University Hospital, Oulu, Finland.
Pasi I
PI
Salmela
Department of Radiology, Oulu University Hospital, Oulu, Finland.
Osmo
O
Tervonen
Department of Radiology, Oulu University Hospital, Oulu, Finland.
Roberto Blanco
RB
Sequeiros
MRI; NET; ablation; laser; liver; metastasis; tumor